| Expression pattern: |
UP |
| Associated gene: |
GAS1, AGO2, SHH, SMO, GLI1 |
| Associated microRNA: |
miR-942-3p |
| Biological function: |
enhances sensitivity to cetuximab; depletion induces resistance; inhibits proliferation and colony formation under cetuximab treatment; increases apoptosis under cetuximab treatment |
| Molecular mechanism: |
ceRNA sponge mechanism: circ-EGFR sponges miR-942-3p, upregulates GAS1, activates Hedgehog signaling to promote cetuximab efficacy |
| Biological pathway or process: |
Hedgehog (promotes); proliferation (inhibits); apoptosis (promotes); ceRNA regulation (promotes); drug response (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; FISH / smFISH; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; MTT; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; Clinical Sample Validation; Cohort Study; Survival Analysis; ROC Analysis; Bioinformatics Analysis; Western Blot |
| Clinical significance: |
tissue-based and plasma-based circ-EGFR stratified responders from non-responders to anti-EGFR therapy (ROC AUC 76.8% in tissue; 76.9% in plasma); circ-EGFR-low patients had shorter PFS following anti-EGFR therapy |
| Description: |
circ-EGFR (hsa_circ_0080230), derived from EGFR, is upregulated in cetuximab responders and cetuximab-sensitive CRC cells and serves as a predictor of anti-EGFR therapy response in mCRC. Functionally, it increases cetuximab sensitivity and promotes apoptosis under cetuximab treatment. Mechanistically, it sponges miR-942-3p to upregulate GAS1, activating Hedgehog signaling to enhance cetuximab efficacy. |
| Confidence score: |
0.8871 |